RWD178 Real-World Treatment Patterns, Healthcare Resource Utilization (HRU) and Costs for Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL): Chimeric Antigen Receptor T-Cell (CAR T) and Monoclonal Antibodies (MAB) Therapies
Abstract
Authors
C. Feng L. Murphy N. Engel-Nitz A. Nguyen A. Patel M. DuCharme C. Fu G. Shah